Related references
Note: Only part of the references are listed.Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
Raghuveer Singh Mali et al.
HAEMATOLOGICA (2021)
Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
Abhishek Maiti et al.
HAEMATOLOGICA (2021)
Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
Xiaojia Niu et al.
BLOOD (2021)
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
Targeting MCL-1 in hematologic malignancies: Rationale and progress
Andrew H. Wei et al.
BLOOD REVIEWS (2020)
Saga of Mcl-1: regulation from transcription to degradation
Viacheslav V. Senichkin et al.
CELL DEATH AND DIFFERENTIATION (2020)
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia
Shanshan Pei et al.
CANCER DISCOVERY (2020)
Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options
Xiaowei Wu et al.
CELL DEATH & DISEASE (2020)
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
Lindsey T. Brinton et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation
Fangbing Liu et al.
CANCERS (2020)
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Shruti Bhatt et al.
CANCER CELL (2020)
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Jenna L. Carter et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells (vol 34, pg 724, 2018)
Courtney L. Jones et al.
CANCER CELL (2019)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
Jun Ma et al.
CLINICAL CANCER RESEARCH (2019)
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Romain Guieze et al.
CANCER CELL (2019)
The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis
Anna Orlova et al.
HAEMATOLOGICA (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus et al.
BLOOD CANCER JOURNAL (2019)
Drug-perturbation-based stratification of blood cancer
Sascha Dietrich et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Time to response and survival in hypomethylating agent-treated acute myeloid leukemia
Prajwal Boddu et al.
LEUKEMIA & LYMPHOMA (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E. Perl et al.
LANCET ONCOLOGY (2017)
Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy
Rongqing Pan et al.
CANCER CELL (2017)
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
Gabriele Nagel et al.
ANNALS OF HEMATOLOGY (2017)
GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo
Caroline Pabst et al.
BLOOD (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
Kevin H. Lin et al.
SCIENTIFIC REPORTS (2016)
Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model
Bhagwan Yadav et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)
An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging
Binje Vick et al.
PLOS ONE (2015)
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Rongqing Pan et al.
CANCER DISCOVERY (2014)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
S. Kasper et al.
BLOOD CANCER JOURNAL (2012)
The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy
Asish K. Ghosh et al.
BLOOD (2011)
FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation
Goichi Yoshimoto et al.
BLOOD (2009)
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
R Zheng et al.
BLOOD (2004)
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
M Mizuki et al.
BLOOD (2000)
Share Paper
